36207-10-0

Upstream product

• 67-56-1 methanol 
• 14387-10-1 (4-ethyl-phenyl)-acetic acid 

Downstream Products

• 1247119-83-0 2-(4-ethylphenyl)-2-methyl-propanoic acid 
• 394207-67-1 C₁₃H₁₆O₄ 
• 210530-69-1 2-(4-ethyl-phenyl)-acrylic acid methyl ester 
• 609352-24-1 Bromo-(4-ethyl-phenyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

Preparation method of alectinib intermediate

The invention discloses a preparation method of 2-(4-ethyl-3-iodine) phenyl-2-methyl propionic acid as an alectinib intermediate. According to the preparation method, the operation danger class and production cost are reduced by optimizing and improving a

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.